Cancer-Associated Venous Thromboembolism in the Real World ― From the COMMAND VTE Registry

Background:There is a paucity of data on the management and prognosis of cancer-associated venous thromboembolism (VTE), leading to uncertainty about optimal management strategies.Methods and Results:The COMMAND VTE Registry is a multicenter registry enrolling 3,027 consecutive acute symptomatic VTE...

Full description

Saved in:
Bibliographic Details
Published inCirculation Journal Vol. 83; no. 11; pp. 2271 - 2281
Main Authors Sakamoto, Jiro, Yamashita, Yugo, Morimoto, Takeshi, Amano, Hidewo, Takase, Toru, Hiramori, Seiichi, Kim, Kitae, Oi, Maki, Akao, Masaharu, Kobayashi, Yohei, Toyofuku, Mamoru, Izumi, Toshiaki, Tada, Tomohisa, Chen, Po-Min, Murata, Koichiro, Tsuyuki, Yoshiaki, Saga, Syunsuke, Nishimoto, Yuji, Sasa, Tomoki, Kinoshita, Minako, Togi, Kiyonori, Mabuchi, Hiroshi, Takabayashi, Kensuke, Yoshikawa, Yusuke, Shiomi, Hiroki, Kato, Takao, Makiyama, Takeru, Ono, Koh, Tamura, Toshihiro, Nakagawa, Yoshihisa, Kimura, Takeshi, on behalf of the COMMAND VTE Registry Investigators
Format Journal Article
LanguageEnglish
Published Japan The Japanese Circulation Society 25.10.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background:There is a paucity of data on the management and prognosis of cancer-associated venous thromboembolism (VTE), leading to uncertainty about optimal management strategies.Methods and Results:The COMMAND VTE Registry is a multicenter registry enrolling 3,027 consecutive acute symptomatic VTE patients in Japan between 2010 and 2014. We divided the entire cohort into 3 groups: active cancer (n=695, 23%), history of cancer (n=243, 8%), and no history of cancer (n=2089, 69%). The rate of anticoagulation discontinuation was higher in patients with active cancer (43.5%, 27.0%, and 27.0%, respectively, at 1 year, P<0.001). The cumulative 5-year incidences of recurrent VTE, major bleeding, and all-cause death were higher in patients with active cancer (recurrent VTE: 17.7%, 10.2%, and 8.6%, P<0.001; major bleeding: 26.6%, 8.8%, and 9.3%, P<0.001; all-cause death: 73.1%, 28.6%, 14.6%, P<0.001). Among the 4 groups classified according to active cancer status, the cumulative 1-year incidence of recurrent VTE was higher in the metastasis group (terminal stage group: 6.4%, metastasis group: 22.1%, under chemotherapy group: 10.8%, and other group: 5.8%, P<0.001).Conclusions:In a current real-world VTE registry, patients with active cancer had higher risk for VTE recurrence, bleeding, and death, with variations according to cancer status, than patients without active cancer. Anticoagulation therapy was frequently discontinued prematurely in patients with active cancer in discordance with current guideline recommendations.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:1346-9843
1347-4820
1347-4820
DOI:10.1253/circj.CJ-19-0515